Welcome to our dedicated page for ASTELLAS PHARMA UNSP/ADR news (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on ASTELLAS PHARMA UNSP/ADR stock.
Astellas Pharma Inc. is a global pharmaceutical company with operations in over 70 countries. The company focuses on creating innovative drugs to treat diseases with high unmet medical needs by emphasizing Biology and Modality. Beyond traditional pharmaceuticals, Astellas is exploring Rx+® healthcare solutions in collaboration with cutting-edge technology partners. Astellas recently opened a state-of-the-art West Coast Innovation Center in South San Francisco, enhancing its commitment to biotech innovation.
The company is actively involved in research and development, with recent advancements in cancer therapies like zolbetuximab, a monoclonal antibody targeting gastric and gastroesophageal cancers. Astellas' collaborations with Pfizer and Merck, as well as YASKAWA Electric Corporation, demonstrate its commitment to pioneering research and creating new treatment paradigms by integrating pharmaceutical and robotics technologies.
Rhea-AI Summary
Astellas Pharma Inc. (TSE: 4503) has announced the approval of VEOZATM (fezolinetant) 45 mg once daily by the European Commission for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, also known as hot flashes and/or night sweats, affect more than half of women aged 40 to 64 years, with rates in Europe ranging from 56% to 97%. The prevalence of moderate to severe VMS in postmenopausal women in Europe has been reported at 40%. The approval follows positive clinical trial results from the BRIGHT SKY™ program, with fezolinetant demonstrating efficacy and safety for the treatment of VMS. Astellas has already reflected the impact from this matter in its financial forecast of the current fiscal year ending March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Summary
Astellas Pharma Inc. (TSE: 4503) will present 24-week results from the Phase 3b DAYLIGHT clinical trial examining the efficacy and safety of fezolinetant, an investigational oral, nonhormonal compound for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women unsuitable for hormone therapy. The study of over 450 women met all primary and secondary endpoints at 24 weeks, demonstrating statistically significant reductions in the frequency and severity of VMS, as well as patient-reported sleep disturbance. Treatment-emergent adverse events were reported by 65% of patients in the fezolinetant group compared to 61% in the placebo group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
-
Rhea-AI Summary
PFE and Astellas Pharma Inc. (4503) announced that the FDA approved a supplemental New Drug Application for XTANDI, making it the first and only androgen receptor signaling inhibitor approved for nonmetastatic castration-sensitive prostate cancer treatment with or without a GnRH analog therapy. This approval follows expedited development and review programs based on results from the Phase 3 EMBARK trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
Rhea-AI Summary
Astellas Pharma Inc. (TSE: 4503) and University of Tsukuba announced a strategic partnership to accelerate the digitalization of drug discovery research and the development of the life science ecosystem in Tsukuba and Kashiwa-no-ha. The partnership aims to promote innovative drug discovery research using AI and digital technologies and create new drug discovery startups. This agreement will facilitate industry-academia collaboration, utilization of research equipment and data, and the establishment of an office for the Tsukuba Digital-Bio International Center at Astellas' SakuLab™-Tsukuba. The collaboration is expected to turbocharge the development of pioneering healthcare solutions in the life science ecosystem.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
-
Rhea-AI Summary
Astellas Pharma Inc. to Acquire PRL-02, a Prostate Cancer Treatment Program Developed by Propella Therapeutics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
-
Rhea-AI Summary
Astellas Pharma Inc. (TSE: 4503) reported preliminary data analysis from the ASPIRO trial, published in The Lancet Neurology, showcasing the safety and efficacy of investigational AT132 for pediatric patients with X-linked myotubular myopathy (XLMTM). The data revealed improvements in ventilator dependence and motor milestones, along with identified liver health issues. The study included 24 boys with XLMTM, showing significant reduction in ventilator support and achievement of major motor milestones post-gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
Rhea-AI Summary
Astellas Pharma Inc. announced positive results from the GATHER2 Phase 3 clinical trial for IZERVAY, demonstrating its effectiveness in reducing the rate of geographic atrophy (GA) lesion growth in patients with age-related macular degeneration (AMD). The treatment effect of IZERVAY more than doubled over 2 years compared to 1 year. The safety profile of IZERVAY was consistent with year 1, with no cases of ischemic optic neuropathy or retinal vasculitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Astellas Pharma to present new research results at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
-
Rhea-AI Summary
Astellas Pharma receives positive opinion from CHMP for fezolinetant as a treatment for vasomotor symptoms associated with menopause.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
Rhea-AI Summary
Astellas Pharma, BioLabs Global, and Mitsui Fudosan have agreed to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan by partnering to advance SakuLabTM-Tsukuba, an open innovation hub. Astellas will prepare experimental facilities for SakuLabTM-Tsukuba in its Tsukuba Research Center and provide networking opportunities for residents and researchers. The impact of this agreement has already been reflected in Astellas' financial forecast for the current fiscal year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
FAQ
What is the current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY)?
The current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY) is $10.09 as of November 22, 2024.
What is the market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY)?
The market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY) is approximately 19.1B.
What is Astellas Pharma Inc. known for?
Astellas Pharma Inc. is recognized as a leading global pharmaceutical company operating in over 70 countries, focusing on developing innovative drugs for diseases with high unmet medical needs.
What recent achievements has Astellas Pharma Inc. made?
Astellas recently inaugurated a modern West Coast Innovation Center in South San Francisco, enhancing its presence in the biotech ecosystem.
What is zolbetuximab, and why is it significant?
Zolbetuximab is an investigational monoclonal antibody aimed at treating gastric and gastroesophageal cancers and is a testament to Astellas' commitment to pioneering cancer therapies.
How does Astellas collaborate with other companies like Pfizer, Merck, and YASKAWA Electric Corporation?
Astellas collaborates with Pfizer, Merck, and YASKAWA Electric Corporation to advance research and development in innovative treatments through partnerships that integrate pharmaceutical and robotics technologies.
What is Astellas Pharma Inc.'s focus beyond traditional pharmaceuticals?
Astellas is exploring Rx+® healthcare solutions with cutting-edge technology partners, aiming to create innovative treatment approaches beyond traditional pharmaceuticals.
ASTELLAS PHARMA UNSP/ADR